Cambridge Healthtech Institute’s Inaugural

Applying 3D Models

Bridging the Gap Between 2D Cell Culture and Animal Models

JUNE 19-20, 2019


Finding physiological relevant models for complex and heterogeneous diseases has never been more important. Cells grown in a monolayer are useful to explore diseases but lack tissue-level structure that is key to mimicking the human body. Animal models have fundamental species differences that decrease their predictive abilities. Join us at Cambridge Healthtech Institute’s Inaugural Applying 3D Models conference as leaders in the field discuss the use of spheroids, tumoroids, organoids, organs-on-a-chip and other microfluidic strategies for drug discovery across several therapeutic areas.

IMPROVING iPSC-BASED TOOLS FOR MODELING

FEATURED PRESENTATION: Modeling Human Disease Using Pluripotent Stem Cells

Lorenz Studer, MD, Director, Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center

Exploring the Utility of iPSC-Derived 3D Cortical Spheroids in the Detection of CNS Toxicity

Colin Choi, PhD, Investigative Toxicologist, Takeda

Talk Title to be Announced

Yishan Sun, PhD, Investigator, Novartis Institutes for BioMedical Research (NIBR)

MICROFLUIDIC TECHNOLOGIES TO SCREEN FOR PATIENT SPECIFIC IMMUNOTHERAPIES

Ex Vivo Profiling of Response to PD-1 Blockade Using Organotypic Tumor Spheroids

Elena Ivanova, PhD, Senior Scientist, Medical Oncology, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute

Cancer Models: Immune Checkpoint Blockade Therapies and Metastatic Disease

Roger D Kamm, PhD, Green Distinguished Professor of Mechanical and Biological Engineering, Depts. of Mechanical Engineering and Biological Engineering, Massachusetts Institute of Technology

TANK-Binding Kinase 1 (TBK1) as a Cancer Immunotherapy Target

Russell W. Jenkins, MD, PhD, Assistant Professor, Dept. of Medicine, Center for Cancer Research, Massachusetts General Hospital

HTS FOR ONCOLOGY

A PDX/Organoid Biobank of Advanced Prostate Cancer for Disease Modeling and Therapeutic Screening

Kathleen Kelly, PhD, Lab Chief, Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute

High Throughput Screening for Spheroids 

Louis Scampavia, PhD, Senior Scientific Director, Molecular Medicine Dept., Scripps Research, Florida Campus


For more details on the conference, please contact:
Mana Chandhok
Conference Producer
Phone: 781-972-1350
Cambridge Healthtech Institute
Email: mchandhok@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com